Jennifer B. Valerin

Jennifer B. Valerin

Hematology | Oncology | Internal Medicine
101 The City Dr S
Bldg 23
Orange, CA 92868

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications

Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.

Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer.

Journal: Journal of vascular and interventional radiology : JVIR
Published: March 28, 2026

The germline MLH1 c.2054 C>T mutation disrupts DNA mismatch repair and is detectable by digital PCR.

The germline MLH1 c.2054 C>T mutation disrupts DNA mismatch repair and is detectable by digital PCR.

Journal: Cancer letters
Published: February 21, 2026

Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors.

Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors.

Journal: Future oncology (London, England)
Published: December 21, 2025

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.

Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer.

Journal: bioRxiv : the preprint server for biology
Published: September 26, 2025

First-line use of antiangiogenic agents in unresectable hepatocellular carcinoma: a double-edged sword?

First-line use of antiangiogenic agents in unresectable hepatocellular carcinoma: a double-edged sword?

Journal: Clinical advances in hematology & oncology : H&O
Published: July 29, 2025

Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience.

Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience.

Journal: Cancer medicine
Published: June 18, 2025

Replacing Liposomal Irinotecan With Standard Irinotecan in Pancreatic Adenocarcinoma: Should We Follow Suit and Substitute Without Dispute?

Replacing Liposomal Irinotecan With Standard Irinotecan in Pancreatic Adenocarcinoma: Should We Follow Suit and Substitute Without Dispute?

Journal: Pancreas
Published: January 31, 2025

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.

Journal: Cells
Published: December 30, 2024

Modulation of Tumor-Associated Macrophages to Overcome Immune Suppression in the Hepatocellular Carcinoma Microenvironment.

Modulation of Tumor-Associated Macrophages to Overcome Immune Suppression in the Hepatocellular Carcinoma Microenvironment.

Journal: Cancers
Published: December 16, 2024

Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.

Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach.

Journal: Cancer medicine
Published: October 09, 2024

The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.

The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma.

Journal: Journal of surgical oncology
Published: May 06, 2024

Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities.

Increased AID Results in Mutations at the CRLF2 Locus Implicated in Latin American ALL Health Disparities.

Journal: Research square
Published: October 04, 2023
Showing 1-12 of 19

Last Updated: 09/26/2026